Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Obinutuzumab for Untreated CLL/SLL
NCT02371590Phase 2Withdrawn
- Sponsor
- University of California, San Diego
- Start
- Feb 2018
- Primary completion
- Dec 2019
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide, obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of California, San Diego. Planned start Feb 2018; status: withdrawn.
02
Drugs
lenalidomideobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02371590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02371590.